Cervical cancer screening and follow-up in 4 geographically diverse US health care systems, 1998 through 2007

Cancer

Volumn 121, Issue 17, 2015, Pages 2976-2983

  Weinmann, Sheila ^a   Williams, Andrew E ^b   Kamineni, Aruna ^c   Buist, Diana S M ^c   Masterson, Erin E ^a   Stout, Natasha K ^d   Stark, Azadeh ^e   Ross, Tyler R ^c   Owens, Christopher L ^f   Field, Terry S ^f   Doubeni, Chyke A ^g  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b Maine Medical Center Research Institute   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e GEISINGER MEDICAL CENTER   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cervical cancer screening; cervical intraepithelial neoplasia; health care delivery systems; human papillomavirus testing; implementation science; Papanicolaou test; screening guideline

Indexed keywords

WART VIRUS VACCINE;

ABLATION THERAPY; ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER SURGERY; COHORT ANALYSIS; DIAGNOSTIC PROCEDURE; FEMALE; FOLLOW UP; HEALTH CARE SYSTEM; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN TISSUE; MIDDLE AGED; PAPANICOLAOU TEST; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREND STUDY; UNITED STATES; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VACCINATION; YOUNG ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIAL; EARLY DIAGNOSIS; HEALTH CARE DELIVERY; MULTICENTER STUDY; UTERINE CERVICAL NEOPLASMS;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; DELIVERY OF HEALTH CARE; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; UNITED STATES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84939568266     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29445     Document Type: Article

References (30)

1. Day NE,. Effect of cervical cancer screening in Scandinavia. Obstet Gynecol. 1984; 63: 714-718.
2. Parkin DM, Nguyen-Dinh X, Day NE,. The impact of screening on the incidence of cervical cancer in England and Wales. Br J Obstet Gynaecol. 1985; 92: 150-157.
3. Gustafsson L, Adami HO,. Cytologic screening for cancer of the uterine cervix in Sweden evaluated by identification and simulation. Br J Cancer. 1990; 61: 903-908.
4. Sigurdsson K,. Effect of organized screening on the risk of cervical cancer. Evaluation of screening activity in Iceland, 1964-1991. Int J Cancer. 1993; 54: 563-570.
5. Laara E, Day NE, Hakama M,. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet. 1987; 1: 1247-1249.
6. Screening for cervical cancer: recommendations and rationale. Am Fam Physician. 2003: 67: 1759-1768.
7. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995). Obstet Gynecol. 2003; 102: 417-427.
8. Saslow D, Runowicz CD, Solomon D, et al,; American Cancer Society. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002; 52: 342-362.
9. Moyer VA,; U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 156: 880-891, W312.
10. Siebers AG, Klinkhamer PJ, Grefte JM, et al., Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA. 2009; 302: 1757-1764.
11. Strander B, Andersson-Ellstrom A, Milsom I, Radberg T, Ryd W,. Liquid-based cytology versus conventional Papanicolaou smear in an organized screening program: a prospective randomized study. Cancer. 2007; 111: 285-291.
12. Scott DR, Hagmar B, Maddox P, et al., Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom. Cancer. 2002; 96: 14-20.
13. Wright TC, Schiffman M, Solomon D, et al., Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2007; 197: 346-355.
14. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ,; ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002; 287: 2120-2129.
15. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D,; ASCCP-Sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007; 11: 201-222.
16. Cuzick J, Myers O, Hunt WC, et al., A population-based evaluation of cervical screening in the United States: 2008-2011. Cancer Epidemiol Biomarkers Prev. 2014; 23: 765-773.
17. Insinga RP, Glass AG, Rush BB,. Pap screening in a U.S. health plan. Cancer Epidemiol Biomarkers Prev. 2004; 13: 355-360.
18. Insinga RP, Glass AG, Rush BB,. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol. 2004; 191: 114-120.
19. Insinga RP, Glass AG, Rush BB,. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol. 2004; 191: 105-113.
20. Kruzikas D, Smith JS, Harley C, Buzinec P,. Costs associated with management of cervical human papillomavirus-related conditions. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1469-1478.
21. Katki HA, Kinney WK, Fetterman B, et al., Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011; 12: 663-672.
22. Katki HA, Schiffman M, Castle PE, et al., Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. J Low Genit Tract Dis. 2013; 17 (5 suppl 1): S36-S42.
23. Field TS, Cernieux J, Buist D, et al., Retention of enrollees following a cancer diagnosis within health maintenance organizations in the Cancer Research Network. J Natl Cancer Inst. 2004; 96: 148-152.
24. Ross TR, Ng D, Brown JS, et al., The HMO Research Network Virtual Data Warehouse: A Public Data Model to Support Collaboration. Available at: http://repository.academyhealth.org/egems/vol2/iss1/2. Accessed March 12, 2014.
25. Sawaya GF, Kerlikowske K, Lee NC, Gildengorin G, Washington AE,. Frequency of cervical smear abnormalities within 3 years of normal cytology. Obstet Gynecol. 2000; 96: 219-223.
26. Sherman ME, Lorincz AT, Scott DR, et al., Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003; 95: 46-52.
27. Buist DS, Tuzzio L, Greenlee RT, et al., PS1-33: Cancer Screening Guideline Development, Implementation and Dissemination: Connection Points for Researchers and Health Care Delivery Systems for Comparative Effectiveness Research. Clin Med Res. 2012; 10: 157.
28. Schabert VF, Ye X, Insinga RP, Singhal PK, Riedel AA,. Five-year routine cervical cancer screening rates and intervals in a US health plan. Curr Med Res Opin. 2008; 24: 2429-2435.
29. Eltoum IA, Roberson J,. Impact of HPV testing, HPV vaccine development, and changing screening frequency on national Pap test volume: projections from the National Health Interview Survey (NHIS). Cancer. 2007; 111: 34-40.
30. Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, Goldie SJ,. Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med. 2008; 168: 1881-1889.